# TMC125HIV1083 - Swallowability of Uncoated 200 mg Etravirine Tablets in HIV-1 Infected Patients

> **NCT01090648** · PHASE1 · COMPLETED · sponsor: **Tibotec Pharmaceuticals, Ireland** · enrollment: 49 (actual)

## Conditions studied

- HIV-Infections

## Interventions

- **DRUG:** etravirine

## Key facts

- **NCT ID:** NCT01090648
- **Lead sponsor:** Tibotec Pharmaceuticals, Ireland
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** 2010-05
- **Final completion:** 2010-05
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2012-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01090648

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01090648, "TMC125HIV1083 - Swallowability of Uncoated 200 mg Etravirine Tablets in HIV-1 Infected Patients". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01090648. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*